8 trading days takes you to the 13th which is a day after Q! earnings so and I'm grasping for straws here if earnings are good and pps pops perhaps warrants would be execised and Cytori raises some much needed capital. I don't hold any warrants just stock but hope those that do, don't have them expire worthless.
What a crazy game this Wall Street Casino is.
Going to reply to myself with another scenario. You stated trading days which takes you to the 13th a day after Q! earnings reported so perhaps they are good and pps will pop and then warrants would be exercised. Crazy game this Wall Street casino.
This might have something to do with it. can't be good.
well north of $100 million of available things we’ve got working on. And how do we measure what we have, what are the nearest term, looking at our needs, what are the nearest term needs, while wearing bifocals and looking ahead and trying to maximize the value creation.
Clearly, we have many times over the need addressable by the existing things that are in our field of activity. And then trying to maximize the quality of how that money comes in, either through strategic or warrants or if we do a financing deal, if we do something with a party that we think is, we think has aligned interests with what we’re doing and bringing in the right amounts to not do things that are negative at overhangs to the company. So that’s the field of what we’re doing in parallel on all those fronts on a daily basis and I hope that’s clear.
I have been re-evaluating my position on Cytori. As there has been much discussion about warrants I would like to post below which came from transcript of 2012 annual shareholders meeting . Considering our current state of affairs with May warrants set to expire and Sept only 5 months away the below concerns me.
Lewis Bosher: My name is Lewis Bosher and I’m a private investor. I address this to Mark Saad. The comments have been made about cash and adding $20-30 million to that cash, with a burn rate calculated in there, would take you to the breakeven level. There have also been comments about the stock price moving up and warrants and stock options converting over to provide another $40 million. So we’re talking about somewhere between 5 quarters and maybe 9 quarters until you reach the breakeven. My question really is, are you counting on the warrants being converted to cash just to breakeven?
Mark Saad: No, we’re not. The number that I mentioned was the aggregate from where we are today. If we look, and I appreciate the question because its an important clarification, that when we look at what are the available sources of that cash, there are either new transactions with corporate or financial parties or existing transactions, like the exercise of those warrants and options.
So what was defined as an aggregate need can be met by any number of things, though the important point being that if you have $70+ million available of the already existing warrants and options, that is one potential source. That can be typically discounted especially when they have average lives of several years. So we focus in on what’s expiring within the next one to two years as more of a near term, realistic, when can you see those realistically exercise. So within that one to two years zone is about $40 million worth.
And no, that is not factored into my estimate of the $20-$30 million at all. And then the additional, other sources when we look at in the aggregate, we believe we have
i did not write this it was written by an excerpt from an article written 2 years ago. glad your pleased with how well things are going. was never interested in selling at three and not mad that i didn't ,
Ten times your wildest dreams!
Was an assessment delivered by Lloyd Dean, Chairman of the Cytori Board of Directors concerning the future stockprice of Cytori, during the annual meeting of shareholders in August 2011. Made at a time that most shareholders were moaning about the lack of execution of Cytori management and exactly this guy- certainly not the least influencial and one of the most respected CEO´s in the healthcare space in the US (Catholic Healthcare West- in charge of 12 Billion of Assets and said to have personal "access" to President Obama)- wanted us to believe that Cytori had an excellent management team, for which as of to date- early March 2012 -due to lacking indications in respect of accomplishments, no substance to that statement has been provided or can be shown.
What Dean (picture) surely has been confronted with in his tenure with Cytori, which has covered a time span of roughly 20 months now, is the incredible potential of ADRCs in general, which becomes clear and evident when one studies the available scientific literature and evidence.
Nonetheless the inability of Cytori management to convince BIG PHARMA partner candidates sofar in jointly developing this incredible potential is very disheartening, but as always the belief is still there that one find day the blind squirrel finally finds his nut and Dean´s assessment of the quality of Cytori management is provided with some "colour".
Untill that time however- in view of scarce (financial) resources for a Company that employs 120 highly paid staff, primarily consisting of directors and vice-presidents, obviously the focus can only lie on issues that are to some extent controllable- i.e. continue to develop what has matured to the largest degree, which happens to be the soft tissue, cardiac and wound healing applications.
hedge when do May warrants expire ? when do sept warrants expire and do you recall the price they are set at ? I'm drawing a blank
totaljim is a basher and a short. he does not hold any shares of cytori and has not been around for quite some time. he shows up when things are going poorly to rub salt in the wounds.jim posts the same thing whenever he does post which is that cellution machine is a centrifuge and worht nothing,so take his posts from the source.While he is correct about what he says about the management team as well as performance to date,but tell us something we don't know.
Mac, Wishing you a speedy recovery. I pray you received the real treatment and are rewarded with a healthier and better quality of life.
not sure why this post would be deserving of a thumbs down unless chuckie just can't help himselfself. perhaps title was misleading as I was givng credit to rongside who posted this.
Scientists sporting white coats and safety gloves are working in a bright Food and Drug Administration (FDA) lab on an incredible project.
They are part of FDA’s MSC Consortium, a large team of FDA scientists studying adult mesenchymal stem cells (MSCs)—cells that could eventually be used to repair, replace, restore or regenerate cells in the body, including those needed for heart and bone repair.
The scientists’ investigational work is unprecedented: Seven labs at FDA's Center for Biologics Evaluation and Research formed the consortium to fill in gaps in knowledge about how stem cells function.
“This research aims to facilitate development of this important class of innovative medical products,” explainsCarolyn A. Wilson, Ph.D., associate director for research at the center. “It’s the first time we’ve done anything like this, and it’s proven to be a very useful approach. It’s worked so well because this is a huge, complicated project that requires expertise in many different technologies and methods.”
The research could ultimately be key to the advancement of personalized medicine, the practice in which medical treatment is tailored to the needs of an individual patient. “It’s not science fiction,” says Steven R. Bauer, Ph.D., chief of the Cellular and Tissue Therapy Branch in FDA’s Office of Cellular Tissue and Gene Therapies. “For me, regenerative medicine is the most exciting part of what we regulate in our office.”
back to top
So What Are Stem Cells?
There are two basic kinds of stem cells that are currently useful in the field of regenerative medicine: multipotent and pluripotent stem cells. Multipotent stem cells are generally taken from adults and can divide and develop into many different cell types. Pluripotent stem cells can develop into any type of cell in the body. Both types could divide to replenish cells damaged by injury, illness or normal wear. When stem cells divide, the new cells can either remain stem cells or develop into a new type of cell with a more specific function.
Two types of pluripotent stem cells exist: human embryonic stem cells and induced pluripotent stem cells, which are created by reprogramming adult cells that had already changed into a mature type of cell.
FDA’s MSC Consortium is not studying stem cells taken from embryos. “We’re looking at a particular kind of multipotent adult stem cell—the MSC—which is being used in a lot of regenerative medicine clinical trials,” adds Bauer.
The group is currently studying eight unique cell lines, each acquired from commercial sources and sourced to one of eight distinct, adult donors. (Males and females age 22 to 47 donated stem cells from bone marrow.)
The cells under study are multipotent: “They can differentiate (mature into) at least three cell types: bone, fat and cartilage, primarily,” Bauer explains. “They can also differentiate into nerve cells, liver cells and a kind of cell called ‘stroma’ that is in the bone marrow and supports blood forming cells. Then, for investigational clinical uses, they’ve been used for repairing hearts, repairing bone and repairing cartilage.”
back to top
Why Is FDA Studying These Cells?
In addition to differentiating into a variety of replacement cell types, MSCs can limit a patient’s immune response. So they can potentially be taken from one human donor and placed into a different recipient with less possibility of rejection.
But growing stem cells and making sure they are safe and effective is challenging, which is one reason why stem-cell based clinical trials have not yet resulted in a marketed product.
“The major challenge is that cells are much more complex than traditional products that FDA regulates. And they have the ability to respond to their environment,” Bauer explains. “Taking them out of the body and manufacturing them—that is, growing large numbers of them—or isolating them can change their biology. And it can change the way they behave if they are put back into the patient.”
For instance, if cells are manufactured in large quantities outside their natural environment, they may become ineffective or develop harmful characteristics. For example, they can produce tumors, severe immune reactions or growth of unwanted tissue. So FDA is trying to develop methods that would predict with more certainty how manufactured or isolated adult stem cells will behave in patients.
back to top
What's Being Done?
In the labs, cells are suspended in a nutrient liquid solution and grown in sterile containers called tissue culture flasks. Cells then multiply and go through three, five or seven generations of growth.
FDA scientists are using a variety of cutting-edge methods to characterize cells and then determine if any of these characteristics can predict the behavior of the cells in biological assays or in animal models. The next step will be to determine if any characteristics they measure will predict the safety or effectiveness of stem-cell based products in patients.
Specifically, scientists will continue studying whether factors such as different methods of growing the cells, donor age or gender affects the cells’ quality and performance. This research will ultimately provide new tools to the community of academic and private industry scientists who are interested in evaluating and developing stem cells into new clinical treatments.
“The consortium has shown that widely accepted ways to identify and characterize MSCs do not reveal some important biological differences between batches of these cells,” Bauer says. So the consortium seeks to demonstrate ways to better characterize MSCs that will be used in clinical trials. That’s important because, if investigators can improve the tools used to characterize MSCs used for clinical trials, the data generated from their studies could also improve because their MSC products will be more predictable, he adds.
And the improved predictability of their products will, in turn, allow FDA scientists to more easily evaluate the safety and effectiveness of new stem cell technologies—a key part of the regulatory science that is the foundation of FDA decisions.
Agency scientists already have published six papers in scientific journals such as Tissue Engineering andCytotherapy. “We’re hoping this project will inspire people to do more research in this area,” Bauer says.
Stem cells, like other medical products intended to treat, cure or prevent disease, require FDA approval before they can be marketed. “It is important for FDA to maintain a sound regulatory science research program to promote the development of safe and effective products in emerging areas that hold great promise,” Bauer says.
“My colleagues and I hope our scientific findings will be helpful in the field of regenerative medicine, including the ability to repair or even replace organs and tissues more safely and effectively than traditional means,” he adds. “Although there are many scientific hurdles to overcome before the use of stem cells reaches its full potential, I think this medicine will eventually have the capacity to do that.”
This article appears on FDA’s Consumer Updates page, which features the latest on all FDA-regulated products.
April 23, 2014
that would be expectations will not be met. For those of you that visit the fas board, i have posted the transcript un the heading a walk down memory lane. Yahoo MB does not allow enough characters to post this here or the link to the actual transcript.
Joey one would think this is very positive news for Cytori. I am completely disillusioned with this investment after almost 5 years and don't know if Cytori mangement team has the ability to work this to the advantage of the company. At this point I expect the worst and hope for the best. With the 1st quarter call coming first or second week of may, i suggest every investor go back and read the transcript from the last call . The expectations are high so perhaps the quick drop in pps is a measure of the likelyhood expectations will be met.
street you need to reset your password and get back on the site to review the many comments on precise and other subjects. The overall tome of the majority of posters is rather negative. Fas has other comments and as I have reiterated to you comments by CYTADRC sum up the feeling accurately.
You need to get back on the board not sure why you would be blocked it is not like Fas to block. Below is a reply to a question I had asked on Cytori so you can get a feel for what is going on that MB
Michael- first- I still do read whats written on the YB. Just not daily, but I inform myself several times per week on the more interesting topics.
Yes- I did read your comments under that heading and thought they were quite interesting and certainly not to be dismissed as impossible, since of course- a take-over is possible anytime, despite the best defenses and poison-pill constructs, that a Company and its BOD puts up.
I do want to remind you of Rickey´s statement when he took over in September last year:
“Cytori’s cell therapy platform has the potential to bring about an entirely new class of therapeutics that are innovative and cost-effective,” said Mr. Rickey. “In the role as chair, my priorities will be to represent the interests of our shareholders and to help guide Cytori’s growth as it aims to become a leading independent global biotechnology organization.”
As I have mentioned on this Board- Rickey has gained the respect of the largest shareholders in Cytori and worked diligently to get rid of CC despite the fact that they have known each other for that long. I think more actions will come from him in the next months and they will most likely determine if Cytori can make it on its own.
At present- in my view- NO WAY can they make it on their own. Their is no talent or money to do so. I think Hedrick is even worse than CC- not to speak of Saad. They really have nothing except for a wealth of technology know-how developed in Europe and Asia.
To monetize that expertise as I said we need MONEY and TALENT.To me BARDA is for the birds (at least for a few years) and the corporate image simply in shambles i.e. requires restoration, a partner or a miracle.
yes that was his comment on precise he was luke warm. if you haven't been on the site recently you should go on and read the posts. he has turned rather negative as i said the post from CYTXADRC is accurate as to the vibe. I also posted a reprint of the transcript from the last conference call under the heading a walk down memory lane. I posted just the Q&A as it will serve as a reminder of what mangement guided on BARDA and other topics. A good baramator for the next call which will happen 1st or 2nd week in May per Meghan.